Search

Displaying results 8201 - 8210 of 9692 in total
  1. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

  2. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

  3. Drug

    NN344

    go.drugbank.com/drugs/DB05115
    Experimental

    NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile.

  4. Drug

    RAV12

    go.drugbank.com/drugs/DB05140
    Investigational

    RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.

  5. Drug

    Gataparsen

    go.drugbank.com/drugs/DB05141
    Investigational

    LY2181308 is a solid. LY2181308 is directed against a molecular target called survivin. LY2181308 is known to target baculoviral IAP repeat-containing protein 5.

  6. Drug

    Cretostimogene grenadenorepvec

    go.drugbank.com/drugs/DB05148
    Investigational

    CG0070 is a solid. CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF.

  7. Drug

    Amilomotide

    go.drugbank.com/drugs/DB05150
    Investigational

    CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's diseas...

  8. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  9. Drug

    CR665

    go.drugbank.com/drugs/DB05155
    Experimental

    Preclinical animal studies suggest that CR665 is a potent analgesic compound. … CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid receptor agonists.

  10. Drug

    SL017

    go.drugbank.com/drugs/DB05156
    Experimental

    SL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis